Personalis, Inc. (PSNL) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights several challenges: reduced revenue guidance, logistical delays, and increased expenses. Despite positive developments like new customer onboarding and potential Medicare reimbursement, the lowered guidance and uncertainties in timelines overshadow the positives. The Q&A session reveals cautious management responses and possible revenue delays into Q1. These factors, combined with increased cash usage and reduced gross margin projections, suggest a negative market reaction in the short term, likely leading to a stock price decline of -2% to -8%.
Key Financial Performance
Revenue $14.5 million in Q3 2025, a 44% decrease compared to $25.7 million in Q3 2024. The decline was driven by a $4.6 million decrease from Natera, a $4.2 million decline from the VA MVP due to task order fulfillment in early 2025, and a $2.5 million decline from biopharma customers.
Biopharma Revenue $13.2 million in Q3 2025, a 16% decrease compared to $15.7 million in Q3 2024. The decline was primarily due to a $6.1 million decrease from Moderna's Phase III melanoma trial, partially offset by increased NeXT Personal MRD revenue.
Clinical Revenue $0.4 million in Q3 2025, compared to $0.3 million in Q3 2024, reflecting a slight increase.
Gross Margin 13.2% in Q3 2025, compared to 34% in Q3 2024. The 20.8% decrease was due to 44% lower revenue volume, reduced fixed cost absorption, and increased clinical test costs in advance of reimbursement.
Operating Expenses $25.2 million in Q3 2025, compared to $23.1 million in Q3 2024. The increase was attributed to higher selling expenses related to clinical test volume growth.
R&D Expense $12.2 million in Q3 2025, compared to $11.7 million in Q3 2024, reflecting a slight increase.
SG&A Expense $13 million in Q3 2025, compared to $11.4 million in Q3 2024, reflecting an increase due to selling expenses.
Net Loss $21.7 million in Q3 2025, compared to $39.1 million in Q3 2024. The prior year's net loss included a $26 million noncash expense related to warrants issued to Tempus.
Cash and Short-term Investments $150.5 million at the end of Q3 2025, with no significant debt other than small equipment loans.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
NeXT Personal test: Delivered 4,388 clinical tests in Q3, a 26% sequential and 364% year-over-year growth. Capable of detecting one single fragment of tumor DNA in a million, enabling earlier detection of cancer recurrence and greater confidence in negative results.
CATE clinical trial: Launched in collaboration with Yale Cancer Center and Translational Breast Cancer Research Consortium to establish clinical utility for ctDNA-guided treatment in high-risk HR-positive HER2-negative breast cancer.
Market opportunity: The market for ultrasensitive cancer tests is expected to grow into a $20+ billion opportunity, with Personalis well-positioned to capture a significant share.
Physician adoption: Over 700 physicians are now ordering NeXT Personal, with high retention rates and growing clinical adoption.
Revenue performance: Q3 revenue was $14.5 million, exceeding estimates. Full-year revenue guidance adjusted to $68-$73 million due to biopharma project variability.
Operational scaling: Achieved primary volume target for the year ahead of schedule, now focusing on scaling operational and commercial foundations.
Win-in-MRD strategy: Focused on accelerating clinical adoption, driving reimbursement through clinical evidence, and leading with biopharma partnerships.
Reimbursement progress: Submitted lung cancer for coverage, with 3 dossiers under review by MolDX, targeting 2 coverage decisions in 2025.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Biopharma project timing variability: The timing of biopharma projects continues to show variability, leading to uneven revenue streams and impacting financial predictability.
Logistical delays in biopharma projects: Logistical delays unique to the quarter have impacted the timing of samples for several large projects, increasing revenue variability.
Decline in biopharma revenue: Biopharma revenue declined by 16% year-over-year, primarily due to the conclusion of Moderna's Phase III melanoma trial and other factors.
Gross margin decrease: Gross margin decreased to 13.2% from 34% year-over-year, driven by lower revenue volume and increased clinical test costs in advance of reimbursement.
Revenue decline from Natera and VA MVP: Revenue from Natera and VA MVP declined significantly due to the winding down of these businesses and fulfillment of prior task orders.
Unreimbursed clinical test costs: Investments in unreimbursed clinical test costs have impacted gross margins, with an 18% margin dilution in the third quarter.
Dependence on reimbursement approvals: Revenue from clinical tests is highly dependent on reimbursement approvals, which have not yet been obtained, leading to reduced revenue estimates.
Market conditions and spending environment: The uneven biopharma spending environment has persisted, creating challenges in securing consistent revenue streams.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance: The company has revised its full-year 2025 revenue guidance to a range of $68 million to $73 million, down from the prior guidance of $70 million to $80 million. This adjustment reflects variability in biopharma project timelines and logistical delays impacting Q4 biopharma revenue.
Clinical Test Volume Growth: The company has achieved its annual target for clinical test volumes a quarter early, with over 4,388 tests delivered in Q3 2025. The focus for the rest of the year is on scaling operational and commercial foundations to prepare for Medicare coverage.
Reimbursement Goals: Personalis has submitted three dossiers for coverage with MolDX, targeting two coverage decisions by the end of 2025. The exact timing depends on MolDX review.
Market Opportunity: The market for ultrasensitive MRD tests is expected to grow into a $20+ billion opportunity, with Personalis well-positioned to capture a significant share.
Biopharma Revenue Growth: MRD biopharma revenue is projected to grow approximately 300% year-over-year, driven by strong demand for NeXT Personal in clinical trials.
Clinical Evidence and Trials: The company is launching the CATE clinical trial with Yale Cancer Center and the Translational Breast Cancer Research Consortium to establish clinical utility for ctDNA-guided treatment in high-risk breast cancer. Additionally, data from Phase III trials (NeoADAURA and LAURA) demonstrate the superiority of NeXT Personal in detecting MRD progression ahead of imaging.
Operational Scaling: Personalis is expanding its in-house sales force to complement its partnership with Tempus, ensuring readiness for the Medicare coverage inflection point.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Chris, you mentioned in the last quarter call, there were a couple of very large customers kind of on the cusp of coming online with you. Could you give us an update on those?
A:Yes, they both came online. One was a significant driver of Q3 numbers, contributing to almost 1/3 of revenue from MRD. The other had some revenue in Q3 and will continue into Q4. Additionally, two large prospective clinical trials with biopharma customers have been signed, which will be serviced over the next 2-3 years.
Q:Chris, in your prepared comments today, you said something about a logistical delay specific to this sector. Could you clarify what you meant by that?
A:There were challenges with samples at customs, possibly due to the government shutdown or other issues. This caused variability and delays, with some samples being turned back. The company widened the revenue range to account for potential delays in processing these samples in Q4, which might slip into Q1.
Q:The NeXT Personal growth was just a hair shy of your previously communicated 30% to 40% a quarter growth coming in at plus 26%. Could you clarify the reasons for this?
A:The company was careful in managing investments ahead of reimbursement and tempered demand. Q3 is typically a slower quarter due to seasonality, and the company chose not to allocate additional resources to push growth further. The goal of 4,800 tests by year-end is still on track.
Q:You lowered the guidance on the clinical revenue contribution here in Q4. Could you characterize your conversations with MolDX and provide an update?
A:The company has had productive conversations with MolDX, with three submissions under review. They expect two approvals by year-end, though there is variability in the timeline. The process involves back-and-forth questions and responses, and the company remains optimistic about achieving its goals.
Q:Could you provide feedback from biopharma regarding MRD technology, particularly the 1 part per million sensitivity?
A:Biopharma companies value the ability to fail faster in early-stage trials, achieve success faster in later-stage trials, and enroll the right patients in clinical trials. The ultrasensitive testing has been well-received, and the company has made significant progress in building a global presence and running large prospective clinical trials.
Q:Is the government shutdown having any impact on MolDX?
A:No impact has been observed so far. MolDX is a private company with a government contract, and operations have continued without disruption.
Q:Can you explain the typical back-and-forth process with MolDX and where the company currently stands?
A:The process involves 60-day cycles of questions and responses. The company has been through multiple cycles for its three submissions (breast, IO, and lung cancer) and expects answers by year-end. The timeline depends on the strength of the evidence and the back-and-forth process.
Q:What is the expected timeline for the TRACERx study publication and colorectal cancer dossier preparation?
A:The TRACERx study is expected to be published in the next quarter. The colorectal cancer dossier is in early stages, and the company plans to work on it next year.
Q:What is the status of Natera's revenue contribution?
A:Natera's revenue contribution has significantly declined and is expected to be minimal in Q4. The company has transitioned to a more diverse biopharma revenue base.
Q:Could you elaborate on the clinical test growth drivers?
A:Growth is driven by both new physician accounts and increased test volume per physician. The company is focusing on deeper penetration within existing accounts rather than expanding the top-line physician base.
Q:Review of Unclear Management Responses
A:Management avoided providing specific numerical guidance for the year 1 or year 2 ramp post-reimbursement approval, citing early stages and market dynamics. Additionally, they did not provide detailed revenue expectations for colorectal cancer dossier preparation or specific timelines for deeper penetration into biopharma accounts.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AstraZeneca Phase
Breast Cancer
CATE trial
Cancer Center
Cancer Research
Center Translational
Conference superiority
Consortium multicenter
DNA improvement
III study
MolDX coverage
Phase III
Win MRD
ability
adoption
biopharma partner
biopharma project
ctDNA
demand trial
disease
dossier review
focus
launch
offering
patient result
physician Personal
pillar
platform
progression
review MolDX
standard care
step
test physician
treatment
ultrasensitivity
utility
value approach
PSNL Transcript
Personalis, Inc. (PSNL) Q1 2026 Earnings Call Transcript
Positive5-8
The earnings call summary reflects strong quarterly growth, with a 26% increase in tests and a clear focus on expanding clinical volumes. The company's confidence in their ultrasensitive testing approach and strategic partnerships, along with improving gross margins and aggressive reimbursement strategies, indicate positive market sentiment. Despite some unclear responses in the Q&A, the overall outlook remains optimistic, especially with upcoming presentations at ASCO and a growing biopharma backlog. These factors suggest a positive stock price movement over the next two weeks.
Personalis, Inc. (PSNL) Q4 2025 Earnings Call Transcript
Unknown2-26
Despite some operational improvements, the earnings call highlighted significant challenges, including a 15% revenue decline and reduced gross margins. Although net loss and cash flow improved, the revised revenue guidance and uncertainties around reimbursement decisions and collaborations present risks. These factors, combined with the absence of positive new developments or partnerships, suggest a negative sentiment overall.
Personalis, Inc. (PSNL) Q3 2025 Earnings Call Transcript
Unknown11-4
The earnings call highlights several challenges: reduced revenue guidance, logistical delays, and increased expenses. Despite positive developments like new customer onboarding and potential Medicare reimbursement, the lowered guidance and uncertainties in timelines overshadow the positives. The Q&A session reveals cautious management responses and possible revenue delays into Q1. These factors, combined with increased cash usage and reduced gross margin projections, suggest a negative market reaction in the short term, likely leading to a stock price decline of -2% to -8%.
Personalis, Inc. (PSNL) Q2 2025 Earnings Call Transcript
Positive8-5
The earnings call summary and Q&A indicate strong growth in MRD products, promising new indications, and strategic partnerships. Despite some challenges in the translational sector and policy headwinds, the company shows resilience with significant revenue growth and optimistic guidance. The Tempus partnership and expansion plans further support a positive outlook. While there are some uncertainties, the overall sentiment leans towards positive due to high growth rates, strategic positioning, and potential reimbursement achievements.
PSNL Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
